Biotech
IRVINE, CA: Manufacturer Has History of Safe, FDA-Compliant Production Free of Consumer Complaints
...
TUSTIN, CA: Statistically Significant Tumor Growth Suppression With Single Agent Bavituximab Equivalent; Statistically Significant Increases in Ratios of Key Indicators of Immune Stimulation With Single Agent Bav ...
SAN DIEGO, CA: Regen Sees Feedback From Presentation and Potential Collaborations Stemming From Conference Invaluable in Further Expansion of the Company's Research
...
TUSTIN, CA: SUNRISE Phase III Lung Cancer Trial for Peregrine's Lead Immuno-Oncology Candidate Bavituximab Operational at Over 150 Sites Worldwide; Data From Immuno-Oncology Development Program Shows Potenti ...
MANCHESTER, NH: The Joslin Diabetes Center in Boston Will Be the Lead Clinic in the Multi-Center, Multi-Country Trial; The Company Expects to Enroll up to 360 Patients in the 24 Week Study, Which Is Expected to Begin ...
TUSTIN, CA: State-of-the-Art Facility Design Using Modular Clean Rooms and Fully-Disposable Technologies Provide Flexibility to Meet Growing Production Demands; Facility Expected to Be Ready for cGMP Production i ...
BEVERLY, MA: Phase 1 Study Demonstrates Prurisol Eligible for FDA 505(b)(2) Regulatory Path
...
HALIFAX, NOVA SCOTIA: DPX-Survivac vaccine is a potential maintenance therapy for newly diagnosed ovarian cancer patients following initial surgery and chemotherapy; future FDA discussions to explore accelerated developmen ...
FORT COLLINS, CO: Interim Phase 1/2 Data Presented at American Society of Hematology
...
